What Are the Symptoms of Ozempic-Related Gastroparesis?
Latest update (2026-01)
FDA enforcement record (Ongoing): Presence of Particulate Matter: Hair was found in a prefilled syringe. [source]
From General Health Awareness to Targeted Legal Action
If you are taking Ozempic and experiencing persistent nausea, vomiting, or abdominal bloating, you may be dealing with gastroparesis—a condition where stomach emptying slows. This page summarizes documented symptoms and timeline information from medical reports and the drug's labeling, building on decades of pharmacovigilance research that connects medication use to specific adverse events. Here we focus on what symptoms to track and when to seek medical evaluation.
Understanding Ozempic and Its Gastrointestinal Effects
Ozempic (semaglutide) is a glucagon-like peptide-1 (GLP-1) receptor agonist approved for glycemic control in type 2 diabetes and for weight management. Its pharmacological action slows gastric emptying, a mechanism that can contribute to gastrointestinal adverse effects. Among these, gastroparesis—a condition characterized by delayed gastric emptying without mechanical obstruction—has been reported in association with Ozempic use. Gastroparesis presents with symptoms such as nausea, vomiting, early satiety, bloating, and abdominal pain. Diagnosis typically involves gastric emptying scintigraphy, which measures the rate at which food leaves the stomach. The clinical presentation can overlap with common gastrointestinal complaints, making recognition challenging. The FDA-approved labeling for Ozempic documents a higher incidence of gastrointestinal adverse reactions compared to placebo. In placebo-controlled trials, gastrointestinal adverse reactions occurred in 15.3% of placebo patients, 32.7% of those receiving Ozempic 0.5 mg, and 36.4% of those receiving Ozempic 1 mg (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). The majority of nausea, vomiting, and diarrhea reports occurred during dose escalation. Discontinuation due to gastrointestinal adverse reactions was higher with Ozempic: 3.1% for 0.5 mg and 3.8% for 1 mg, compared to 0.4% for placebo (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). In a trial comparing Ozempic 1 mg and 2 mg, gastrointestinal adverse reactions occurred in 30.8% and 34.0% of patients, respectively (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). Additional gastrointestinal adverse reactions reported at frequencies below 5% include dyspepsia (1.9% placebo, 3.5% 0.5 mg, 2.7% 1 mg), eructation (0%, 2.7%, 1.1%), flatulence (0.8%, 0.4%, 1.5%), gastroesophageal reflux disease (0%, 1.9%, 1.5%), and gastritis (0.8%, 0.8%, 0.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). While gastroparesis is not explicitly listed in these tables, the symptoms and mechanisms overlap significantly.
Mechanistic Link and Risk Context
Mechanistically, GLP-1 receptor agonists like Ozempic delay gastric emptying by inhibiting antral contractions and stimulating pyloric tone. This effect is dose-dependent and can persist with chronic use. In susceptible individuals, this pharmacological action may lead to clinically significant gastroparesis. The timeline between exposure and documented harm varies. Symptoms often emerge during dose escalation, as noted in clinical trials, but delayed presentations are possible. Patients may experience persistent nausea, vomiting, and abdominal discomfort weeks to months after starting Ozempic. The condition can become chronic, requiring medical intervention such as dietary modifications, prokinetic agents, or, in severe cases, gastric electrical stimulation. Regarding risk anchors, the adequacy of warnings about Ozempic and gastroparesis is a key consideration. The FDA label does not specifically mention gastroparesis as an adverse reaction. Instead, it lists gastrointestinal adverse reactions such as nausea, vomiting, diarrhea, dyspepsia, and gastroesophageal reflux disease (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). The label also includes a warning about serious hypersensitivity reactions, including anaphylaxis and angioedema (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). However, the absence of a specific warning for gastroparesis may leave patients and healthcare providers unaware of this potential risk. This gap in labeling could be relevant in legal contexts, as it may affect whether the manufacturer provided adequate warnings.
Virginia Statute of Limitations for Ozempic Gastroparesis Claims
For affected patients in Virginia, attorney-related considerations include the statute of limitations for product liability claims. In Virginia, the statute of limitations for personal injury claims, including those related to defective drugs, is generally two years from the date of injury or from when the injury was discovered or reasonably should have been discovered. This timeline is critical for patients who developed gastroparesis after using Ozempic. The date of discovery may be when a healthcare provider diagnosed gastroparesis and linked it to Ozempic use. Patients should seek legal advice promptly to ensure their claim is filed within the applicable time frame. The timeline between exposure and documented harm is another factor. Clinical trial data show that gastrointestinal adverse reactions often occur during dose escalation, but individual cases may vary. Patients who experience persistent symptoms after starting Ozempic should document the onset and progression of symptoms, as well as any medical evaluations. This documentation can help establish a causal link between the drug and the harm. In summary, Ozempic use is associated with gastrointestinal adverse reactions, including symptoms consistent with gastroparesis. The FDA label does not specifically warn about gastroparesis, which may raise questions about the adequacy of warnings. Patients in Virginia who develop gastroparesis after using Ozempic should be aware of the two-year statute of limitations and consult an attorney to evaluate their legal options. The mechanistic link between GLP-1 receptor agonists and delayed gastric emptying supports the plausibility of this adverse effect, and the timeline of symptom onset should be carefully documented. References (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166)
Important Notice
This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.
Frequently Asked Questions
What is the statute of limitations for an Ozempic gastroparesis lawsuit in Virginia?
In Virginia, the statute of limitations for personal injury claims, including product liability cases related to Ozempic, is generally two years from the date of injury or from when the injury was discovered or reasonably should have been discovered. For gastroparesis, the date of discovery is often when a healthcare provider diagnoses the condition and links it to Ozempic use. It is crucial to consult an attorney promptly to ensure your claim is filed within this time frame.
Does the FDA label for Ozempic warn about gastroparesis?
The FDA-approved label for Ozempic does not specifically mention gastroparesis as an adverse reaction. It lists gastrointestinal adverse reactions such as nausea, vomiting, diarrhea, dyspepsia, and gastroesophageal reflux disease (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). The absence of a specific warning for gastroparesis may be relevant in legal contexts regarding the adequacy of warnings provided by the manufacturer.
Does submitting information create an attorney-client relationship?
No. Submission requests an initial records screening only and does not create an attorney-client relationship.
This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.
Community Resource & Benefit Desk
Request archival records or inquire about member-exclusive transition and benefit programs.
Free Case & Eligibility Review
Individuals with documented archive exposure and a related diagnosis may request an independent, no-cost eligibility review.